title: Single-agent thalidomide for treatment of first relapse following high-dose chemotherapy in patients with multiple myeloma.
authors.forename: R
authors.initials: R
authors.lastname: Fenk
authors.forename: B
authors.initials: B
authors.lastname: Hoyer
authors.forename: U
authors.initials: U
authors.lastname: Steidl
authors.forename: M
authors.initials: M
authors.lastname: Kondakci
authors.forename: T
authors.initials: T
authors.lastname: Graef
authors.forename: R
authors.initials: R
authors.lastname: Heuk
authors.forename: L
authors.initials: L
authors.lastname: Ruf
authors.forename: C
authors.initials: C
authors.lastname: Strupp
authors.forename: F
authors.initials: F
authors.lastname: Neumann
authors.forename: U-P
authors.initials: UP
authors.lastname: Rohr
authors.forename: B
authors.initials: B
authors.lastname: Hildebrandt
authors.forename: R
authors.initials: R
authors.lastname: Haas
authors.forename: G
authors.initials: G
authors.lastname: Kobbe
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D009101:Multiple Myeloma / Q000188:drug therapy*; D012008:Recurrence; D013792:Thalidomide / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D013792:Thalidomide